AGENT FOR ALLEVIATING STRESS-INDUCED BOWEL DISORDER CONTAINING SPECIFIC LACTOBACILLUS GASSERI STRAIN OR TREATED PRODUCT THEREOF
The present application provides Lactobacillus gasseri CP2305 strain (FERM BP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or, a derivative strain (for example, a cold-tolerant derivative strain) derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain, a method for producing the same, a stress-induced bowel disorder-alleviating agent comprising the derivative strain, a treated product thereof, or a mixture thereof as an active ingredient, and food additives, animal additives, animal feeds, and pharmaceutical compositions containing the agent.
1 . An agent for alleviating excessive water secretion in the bowels, stress-induced diarrhea, stress-induced bowel disorder, irritable bowel syndrome, or inflammatory bowel disease, comprising as an active ingredient Lactobacillus gasseri CP2305s strain (NITE BP-1405) or a derivative strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain (NITE BP-1405), a treated product thereof, or a mixture thereof.
2 . An agent for alleviating excessive water secretion in the bowels or stress-induced diarrhea, comprising as an active ingredient Lactobacillus gasseri CP2305 strain (FERM BP-11331), a treated product thereof, or a mixture thereof.
3 . An agent for alleviating excessive water secretion in the bowels, stress-induced diarrhea, or stress-induced bowel disorder, comprising as an active ingredient sterilized cells of Lactobacillus gasseri CP2305 strain (FERM BP-11331), a treated product thereof, or a mixture thereof.
4 . The agent according to claim 1 or 2 , wherein the cells of the CP2305 strain, the CP2305s strain, or a derivative strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain (NITE BP-1405) are living cells or sterilized cells.
5 . The agent according to any one of claims 1 to 4 , wherein the treated product is dried cells, broken cells, disrupted cells, or in the form of fermented milk.
6 . The agent according to any one of claims 1 to 5 , which has an effect of inhibiting the stress-induced suppression of pelvic (parasympathetic) neural activity.
7 . The agent according to any one of claims 1 to 6 , which has an effect of suppressing water secretion by suppressing the chloride channels of the large intestine.
8 . The agent according to any one of claims 1 to 7 , which is an agent for improving stress-induced diarrhea.
9 . A method for producing an animal feed, comprising a step of producing an animal feed by mixing the agent according to any one of claims 1 to 8 with an animal feed ingredient.
10 . An animal feed, comprising living cells or sterilized cells of Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a derivative strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain (NITE BP-1405), a treated product thereof, or a mixture thereof.
11 . A food additive or an animal feed additive, comprising the agent according to any one of claims 1 to 10 .
12 . A food additive, comprising living cells or sterilized cells of Lactobacillus gasseri CP2305 strain (FERM BP-11331), Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a derivative strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain, a treated product thereof or a mixture thereof.
13 . A food or drink, comprising living cells or sterilized cells of Lactobacillus gasseri CP2305s strain (NITE BP-1405) or a derivative strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain, a treated product thereof, or a mixture thereof.
14 . The food or drink according to claim 13 , which is a functional food or drink.
15 . A method for producing a functional food or drink, comprising mixing the agent according to any one of claims 1 to 8 with a carrier, an excipient, or a diluent for foods, and optionally mixing the same further with a food additive.
16 . A pharmaceutical composition for preventing, alleviating or suppressing, or treating excessive water secretion in the bowels, stress-induced diarrhea, stress-induced bowel disorder, irritable bowel syndrome, or inflammatory bowel disease, comprising as an active ingredient living cells or sterilized cells of Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a derivative strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain, a treated product thereof, or a mixture thereof.
17 . A pharmaceutical composition for preventing, alleviating or suppressing, or treating excessive water secretion in the bowels or stress-induced diarrhea, comprising as an active ingredient Lactobacillus gasseri CP2305 strain (FERM BP-11331), a treated product thereof, or a mixture thereof.
18 . A pharmaceutical composition for preventing, alleviating or suppressing, or treating excessive water secretion in the bowels, stress-induced diarrhea, or stress-induced bowel disorder, comprising as an active ingredient sterilized cells of Lactobacillus gasseri CP2305 strain (FERM BP-11331), or a treated product thereof, or a mixture thereof.
19 . A pharmaceutical composition for preventing, alleviating or suppressing, or treating excessive water secretion in the bowels, stress-induced diarrhea, stress-induced bowel disorder, irritable bowel syndrome, or inflammatory bowel disease, comprising the agent according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier, excipient or diluent.
20 . A lactic acid bacterium, which has an effect of alleviating stress-induced bowel disorder to a degree equivalent to or higher than that of Lactobacillus gasseri CP2305 strain (FERM BP-11331) or Lactobacillus gasseri CP2305s strain (NITE BP-1405), and differs from the CP2305 strain.
21 . The lactic acid bacterium according to claim 20 , which has an effect of alleviating the stress-induced bowel disorder that is an effect of suppressing stress-induced diarrhea to a degree equivalent to or higher than that of Lactobacillus gasseri CP2305 strain (FERM BP-11331) or Lactobacillus gasseri CP2305s strain (NITE BP-1405) in terms of the diarrhea score described in Example 3 of the Description.
22 . A lactic acid bacterium, which suppresses stress-induced diarrhea significantly (p<0.05 vs placebo) compared with a placebo when the diarrhea score is evaluated by the method described in Example 3 of the Description, and differs from the CP2305 strain (FERM BP-11331).
23 . The lactic acid bacterium according to any one of claims 20 to 22 , which is cold-tolerant such that the survival rate when the bacterium is kept on ice for 5 hours is 60% or higher.
24 . The lactic acid bacterium according to any one of claims 20 to 23 , which has an effect of inhibiting the stress-induced suppression of pelvic (parasympathetic) neural activity.
25 . The lactic acid bacterium according to any one of claims 19 to 24 , which has an effect of suppressing water secretion by suppressing the chloride channels of the large intestine.
26 . The lactic acid bacterium according to any one of claims 20 to 25 , wherein the lactic acid bacterium is a lactic acid bacterium belonging to the species Lactobacillus gasseri.
27 . The lactic acid bacterium according to any one of claims 20 to 26 , wherein the lactic acid bacterium is Lactobacillus gasseri CP2305s strain (NITE BP-1405), a derivative strain of Lactobacillus gasseri CP2305 strain (FERM BP-11331), or a derivative strain of Lactobacillus gasseri CP2305s strain (NITE BP-1405).
28 . The lactic acid bacterium according to any one of claims 20 to 27 , which is used for preventing or alleviating excessive water secretion in the bowels, stress-induced diarrhea, stress-induced bowel disorder, irritable bowel syndrome, diarrhea-predominant irritable bowel syndrome, or inflammatory bowel disease.
29 . A method for producing a cold-tolerant lactic acid bacterial strain, comprising exposing a lactic acid bacterium to a temperature at 10° or lower, selecting a cold-tolerant strain that has survived, breeding, optionally repeating the steps, and collecting a cold-tolerant strain that has survived.
30 . The method according to claim 29 , wherein the lactic acid bacterium is a lactic acid bacterium belonging to the species Lactobacillus gasseri , or a lactic acid bacterium of Lactobacillus gasseri CP2305 strain (FERM BP-11331).
31 . A lactic acid bacterium, which is Lactobacillus gasseri CP2305s strain (NITE BP-1405), or a derivative strain derived from Lactobacillus gasseri CP2305 strain (FERM BP-11331) or the CP2305s strain.
32 . A lactic acid bacterium, which is cold-tolerant such that the survival rate when the bacterium is kept on ice for 5 hours is 60% or higher.
33 . The lactic acid bacterium according to claim 32 , wherein the lactic acid bacterium belongs to the species Lactobacillus gasseri.
34 . An agent for preventing or alleviating excessive water secretion in the bowels, stress-induced diarrhea, stress-induced bowel disorder, irritable bowel syndrome, diarrhea-predominant irritable bowel syndrome, or inflammatory bowel disease, comprising as an active ingredient the lactic acid bacterium according to any one of claims 20 to 27 and 31 to 33 .